Fig. 4

Characterization of mutations across TP53, ATR, ATM, CHEK1 and CHEK2: (A) shows the novel mutations, (B) the distribution of germline versus somatic mutations; (C) the types of mutations observed within the cohort; and (D) mutations with potential biomarker applications.